For in vitro-in vivo extrapolation (IVIVE) of drug absorption, distribution, metabolism, excretion (ADME), pharmacodynamics (PD) and drug-drug interactions (DDI), quantitative systems pharmacology (QSP) models, including physiologically-based pharmacokinetic (PBPK) models, rely heavily on physiological parameters, such as the abundance of proteins in tissues important in these processes. A significant obstacle in quantification of the abundance of ADME and PD proteins is that conventional methods (e.g. Western blotting) cannot be used when purified standards of these proteins (e.g. transporters, receptors) are not available. Moreover, these conventional methods lack specificity, are low throughput and cumbersome. The advent of quantitative proteomics, based on LC-MS/MS, has overcome many of these disadvantages. Though this approach is increasingly being adopted by many laboratories, differences in its implementation have led to large differences in the reported abundance of ADME proteins. Therefore, the goals of this ISSX workshop are three-fold. First, to have key opinion leaders with extensive experience with quantitative proteomics share their viewpoints and debate the best practices in its implementation; second, to publish a consensus “white paper” on these best practices; and third, to educate scientists interested in implementing quantitative proteomics in their laboratories on the choices, advantages, disadvantages and pitfalls of quantitative proteomics.
27 Sep 2018 → 28 Sep 2018
ISSX Workshop: Towards Reaching a Consensus on Using Quantitative LC-MS/MS Proteomics in Translational DMPK/PD Research
|Event duration||27 Sep 2018 → 28 Sep 2018|
|Location of event||Takeda Pharmaceuticals USA Inc.|
|Degree of recognition||International event|